Molecular-Clinical Correlation in Pediatric Medulloblastoma: A Cohort Series Study of 52 Cases in Taiwan

• Main Authors: Kuo-Sheng Wu, Donald Ming-Tak Ho, Shiann-Tarng Jou, Alice L. Yu, Huy Minh Tran, Muh-Lii Liang, Hsin-Hung Chen, Yi-Yen Lee, Yi-Wei Chen, Shih-Chieh Lin, Feng-Chi Chang, Min-Lan Tsai, Yen-Lin Liu, Hsin-Lun Lee, Kevin Li-Chun Hsieh, Wen-Chang Huang, Shian-Ying Sung, Che-Chang Chang, Chun Austin Changou, Kung-Hao Liang, Tsung-Han Hsieh, Yun-Ru Liu, Meng-En Chao, Wan Chen, Shing-Shung Chu, Er-Chieh Cho, Tai-Tong Wong
• Format: Article
• Language: English
• Published: MDPI AG 2020-03-01
• Series: Cancers
• Subjects: medulloblastoma; molecular–clinical correlation; risk stratification; rna-seq; somatic mutations; dna damage response; genetic predisposition
• Online Access: https://www.mdpi.com/2072-6694/12/3/653

In 2016, a project was initiated in Taiwan to adopt molecular diagnosis of childhood medulloblastoma (MB). In this study, we aimed to identify a molecular-clinical correlation and somatic mutation for exploring risk-adapted treatment, drug targets, and potential genetic predisposition. In total, 52 frozen tumor tissues of childhood MBs were collected. RNA sequencing (RNA-Seq) and DNA methylation array data were generated. Molecular subgrouping and clinical correlation analysis were performed. An adjusted Heidelberg risk stratification scheme was defined for updated clinical risk stratification. We selected 51 genes for somatic variant calling using RNA-Seq data. Relevant clinical findings were defined. Potential drug targets and genetic predispositions were explored. Four core molecular subgroups (WNT, SHH, Group 3, and Group 4) were identified. Genetic backgrounds of metastasis at diagnosis and extent of tumor resection were observed. The adjusted Heidelberg scheme showed its applicability. Potential drug targets were detected in the pathways of DNA damage response. Among the 10 patients with SHH MBs analyzed using whole exome sequencing studies, five patients exhibited potential genetic predispositions and four patients had relevant germline mutations. The findings of this study provide valuable information for updated risk adapted treatment and personalized care of childhood MBs in our cohort series and in Taiwan.